Business · Malaysia Bureau
Cellmax unveils locally-developed wound care range after eight-year development
The Malaysian medical technology company has launched a suite of wound care products following extensive research and substantial investment. The products have received regulatory approval from the Medical Device Authority.
LSN Malaysia ·
Cellmax has introduced a new line of wound care products developed entirely in Malaysia, marking a significant milestone for the country's medical device sector. The product range represents the culmination of eight years of dedicated research and development, supported by an investment of RM7 million.
The company's wound care offerings have successfully completed regulatory requirements and obtained registration with the Medical Device Authority, clearing the way for commercial distribution. This approval underscores the quality and safety standards maintained throughout the development process.
The launch reflects growing momentum in Malaysia's healthcare innovation landscape, with local companies increasingly investing in research to develop solutions tailored to regional medical needs. Cellmax's commitment to domestic development positions the company to serve the broader Southeast Asian market while supporting the nation's goals of advancing its medical technology industry.
The wound care products are expected to become available through established healthcare distribution channels, offering medical professionals and facilities locally-developed alternatives in this critical care category.